Liu Wu, Kim Jenna May, Young Benjamin K, Nath Ravinder, Chen Zhe, Decker Roy H, Astrahan Melvin A, Pointdujour-Lim Renelle
Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, Connecticut, USA.
Yale Smilow Cancer Center, Yale University School of Medicine, New Haven, Connecticut, USA.
Ocul Oncol Pathol. 2019 Apr;5(3):220-227. doi: 10.1159/000493269. Epub 2018 Oct 11.
While traditional eye plaque brachytherapy can be used for the treatment of iris melanoma, it faces challenges of poor patient tolerability due to cornea-plaque touch caused by radius of curvature mismatch and potential dosimetric inaccuracy from incomplete coverage. We present novel plaque designs and the first clinical application of the plaques for iris melanoma.
Two dome-shaped plaques (EP2132 and EP1930) were designed to vault above the cornea to treat tumors of the iris and ciliary body. Image-based treatment planning of the first 2 clinical cases using the EP2132 plaque covered the tumor base plus a 2 mm margin and the involved ciliary body with at least 75 Gy to the tumor apex.
The tumors decreased in size following treatment. The patients tolerated the treatment well. There was no adverse event associated with the traditional iris plaques, such as decreased vision, pain, corneal edema, glaucoma, or cataract.
The novel dome-shaped plaques for the treatment of iris melanoma provide effective dose distribution, improved surgical maneuverability, and increased tolerability for the patient. This plaque model can be used to treat iris melanoma of various sizes, configurations, and locations, including the ciliary body. The need for a customized plaque platform for each patient is minimized.
虽然传统眼部敷贴近距离放疗可用于治疗虹膜黑色素瘤,但由于曲率半径不匹配导致角膜与敷贴接触,以及覆盖不完全可能导致剂量测定不准确,从而面临患者耐受性差的挑战。我们展示了新型敷贴设计以及这些敷贴在虹膜黑色素瘤治疗中的首次临床应用。
设计了两种穹顶形敷贴(EP2132和EP1930),以在角膜上方隆起,用于治疗虹膜和睫状体肿瘤。使用EP2132敷贴对前2例临床病例进行基于图像的治疗计划,覆盖肿瘤基底加2毫米边缘以及受累睫状体,肿瘤顶点至少接受75 Gy照射。
治疗后肿瘤体积减小。患者对治疗耐受性良好。未出现与传统虹膜敷贴相关的不良事件,如视力下降、疼痛、角膜水肿、青光眼或白内障。
用于治疗虹膜黑色素瘤的新型穹顶形敷贴提供了有效的剂量分布,改善了手术操作性,并提高了患者的耐受性。这种敷贴模型可用于治疗各种大小、形态和位置的虹膜黑色素瘤,包括睫状体。将为每个患者定制敷贴平台的需求降至最低。